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Abstract
Background: Mass drug administration (MDA) of antibiotics is a key component of the so-called ‘‘SAFE’’ strategy for
trachoma control, while MDA of anthelminthics provides the cornerstone for control of a number of other neglected
tropical diseases (NTDs). Simultaneous delivery of two or more of these drugs, renowned as ‘‘integrated NTD control,’’ is
being promoted to reduce costs and expand intervention coverage. A cost analysis was conducted alongside an MDA
campaign in a remote trachoma endemic area, to inform budgeting for NTD control in South Sudan.
Methods and Findings: A first round of antibiotic MDA was conducted in the highly trachoma endemic county of Mayom,
Unity state, from June to August 2010. A core team of seven staff delivered the intervention, including recruitment and
training of 44 supervisors and 542 community drug distributors. Using an ingredients approach, financial and economic
costs were captured from the provider perspective in a detailed costing database. Overall, 123,760 individuals were treated
for trachoma, resulting in an estimated treatment coverage of 94%. The economic cost per person treated was USD 1.53,
excluding the cost of the antibiotic azithromycin. Ninety four per cent of the delivery costs were recurrent costs, with
personnel and travel/transport costs taking up the largest share.
Conclusions: In a remote setting and for the initial round, MDA of antibiotics was considerably more expensive than USD
0.5 per person treated, an estimate frequently quoted to advocate for integrated NTD control. Drug delivery costs in South
Sudan are unlikely to decrease substantially during subsequent MDA rounds, as the major cost drivers were recurrent costs.
MDA campaigns for delivery of one or more drugs in South Sudan should thus be budgeted at around USD 1.5 per person
treated, at least until further costing data for delivery of other NTD drugs, singly or in combination, are available.
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Introduction
Since 2007, financial support for the control or elimination of
some key neglected tropical diseases (NTDs) has increase
substantially [1–4]. The NTDs largely benefitting from this
attention are onchocerciasis, lymphatic filariasis (LF), soil-trans-
mitted helminth infections, schistosomiasis and trachoma. The
rationale for focusing on this group of diseases is based on the fact
that safe and effective preventive chemotherapy (PCT) options are
available for all of them, either free of charge or at low cost, and
on the assumption that previously separate distributions of these
drugs by stand-alone vertical programmes could be easily
combined under one structure or become part of other large-
scale distributions of public health commodities such as insecti-
cide-treated mosquito nets, hence substantially reducing delivery
costs [5]. A figure of around USD 0.5 per person treated per year
for co-administration of PCT has been extensively used for
advocacy [6–8], while there is limited empirical evidence
supporting this estimate [9–11]. For programmatic purposes,
particularly to budget for scale up of PCT delivery to previously
untreated areas, there is thus a need to collect accurate cost data.
Furthermore there is a need to develop systems for routine
collection of NTD programme cost data to determine whether
economies of scale and/or scope exist and to estimate the cost-
effectiveness and cost-benefit of stand-alone and ‘integrated’ NTD
control programmes [12].
Investigations into the cost and cost-effectiveness of PCT
delivery for the above diseases have been undertaken to varying
degrees, depending on the availability of data and the principal
interest of the researchers undertaking the analyses. Delivery costs
for large-scale deworming through schools in Kenya, for example,
have been estimated at USD 0.23 per child treated with
albendazole or USD 0.95 for combined albendazole and
praziquantel treatment (both estimates including the cost of the
drug) [13]. Estimates of delivery costs for mass drug administration
(MDA) of anthelminthics from other countries have ranged from
USD 0.03 to USD 0.54 [10,13,14,15]. Similar cost estimates have
been arrived at for MDA campaigns aimed at LF elimination,
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the per capita cost of Haiti’s first MDA round [12]. As frequently
encountered with economic analyses, these results are not
necessarily readily comparable, as investigators choose to use
different costing perspectives and approaches [16]. The results
generated may thus not be suitable for budgeting purposes.
For trachoma, a number of cost and cost-effectiveness studies
have been conducted [17–22] and detailed guidance on how to
conduct a cost-effectiveness analysis for this disease has been
provided [23]. The present study aimed to build on this evidence by
generating critical information on the per-capita cost of imple-
menting a MDA campaign for trachoma. The intervention was
supported by the United States Agency for International Develop-
ment Neglected Tropical Disease (NTD) Control Program and
delivered in a remote trachoma endemic area of South Sudan that
hadnot benefitedfromintervention. Cost data specifictothis setting
wasrequiredtopredictthelikelycost ofrepeatingthisexerciseinthe
same area, scaling up antibiotic distribution to other trachoma
endemic areas of the country and to provide a general estimate of
how much it might cost to deliver one or more drugs for NTD
control through campaigns in this post-conflict setting.
Methods
Ethical Considerations
The MDA campaign was conducted on behalf of the Ministry of
Health, Government of South Sudan (MoH-GoSS), and in close
collaboration with state and county MoH representatives.
Implementation followed treatment guidelines provided by ITI
and WHO [24,25]. The costing study only used data on
expenditures and non-financial inputs incurred by Malaria
Consortium in the implementation of the campaign. Collection
of these data did not involve human subjects and therefore did not
require ethical approval.
MDA Description
The overall purpose of the MDA campaign was to deliver
antibiotics to the highest possible number of individuals eligible for
treatment in an area of South Sudan shown to have prevalences of
57.5% and 39.8%, respectively, of trachomatous inflammation-
follicular and trachomatous inflammation-intense in children aged
1–9 years. In the same area, the prevalence of trachomatous
trichiasis in adults was found to be 19.2% [26].
The International Trachoma Initiative (ITI) recommends at
least 90% of the population should be treated with antibiotics to
lower the risk of recurrent infection [24]. Children below six
months of age should be treated with tetracycline eye ointment for
six weeks (by their parents or care taker), while older children and
adults should receive a single dose of azithromycin. To minimize
the risk of choking on tablets, children age six months to five years
are generally provides with a paediatric oral suspension (POS)
formulation of azithromycin, while older children and adults
receive the drug in tablet form. For both formulations the dose was
determined according to height by means of a gradated dose pole,
as recommended by ITI and WHO [24,25].
Between June and August 2010, 417 villages in all ten payams of
Mayom County, Unity State, received antibiotics (azithromycin
and tetracycline) through a MDA campaign. South Sudan has a
four-tier administrative structure comprised of states (1
st), counties
(2
nd), payams (3
rd) and bomas (4
th). The rainy season in this part of
the country starts in about May, which unfortunately meant that
the majority of fieldwork had to be conducted during the worst
season for implementation. Ideally, implementation would have
been conducted during the dry season, but in the present case this
was not feasible due to various logistical and financial delays.
A core team led by a MDA coordinator and consisting of six
training and treatment supervisors (TATS) conducted the
campaign. A Malaria Consortium field officer and a logistician
also supported the team at various stages of the MDA, amounting
to a total of 30 and 22 days, respectively. In addition, 542
community drug distributors (CDDs) and 44 supervisors were
recruited and trained in the process; both of these staff categories
were paid an incentive, while the core team and their support staff
were on full salaries.
The number of CDDs required to treat each boma was
calculated using population data from the 2008 national census.
Approximately one CDD was recruited for every 40 households or
240 people (as the average household size was estimated to be six
people). Two CDDs were paired up for the duration of the
campaign to ensure that at least one from each pair lived in the area
to be treated and that at least one was literate. Each CDD had to
attend a three-day training session to acquire a basic background on
trachoma and its treatment, and be informed of his/her role in the
MDA. The CDD’s role was to conduct a census of their allocated
households, pick up drugs from an agreed location, return to and
correctly treat their allocated households, and return equipment,
drugs and the census and treatment registers to a Malaria
Consortium staff member. Each CDD was provided with a set of
equipment at the end of the training: T-shirt, ID card, backpack,
pens/pencils/erasers, notebook, clipboard, plastic folder, census
and treatment register, and spray paint/stickers to mark houses that
had been treated. Each pair of CDDs was also given a trachoma flip
chart to facilitate health education sessions, a wooden dose pole to
determine the amount of azithromycin to be given to each
individual, a cup, and water purification tablets to treat all drinking
waterbeforeitwasgiven out to facilitate swallowingofazithromycin
tablets. Supervisors were provided with the same equipment as
CDDs, as well as with a pair of gumboots and a raincoat. They were
also loaned a bicycle for the duration of the MDA in their payam
(usually around ten days).
Two Land Cruiser HZJ Troop Carriers (Toyota Motor
Corporation, Toyota City, Aichi, Japan) owned by Malaria
Author Summary
Trachoma is one of a group of so-called ‘‘neglected
tropical diseases’’ (NTDs) for which safe and effective
treatments are available. The International Trachoma
Initiative oversees donation of the antibiotic azithromycin
to endemic countries. Delivery of this drug to communities
affected by trachoma is the responsibility of national
programmes and their implementing partners, and should
be conducted as part of a comprehensive control strategy
termed ‘‘SAFE,’’ which includes trichiasis surgery, health
education and water/sanitation interventions. There are
little data on how much the different components of a
trachoma control programme cost and none from South
Sudan. To inform budgeting to scale up control of
trachoma, and of other NTDs whose control relies on
large-scale mass drug administration (MDA), the present
study set out to determine the cost per person treated
when antibiotics were delivered through a vertical
campaign that covered 94% of the target population in
a remote trachoma endemic area of South Sudan. The
average economic cost per person treated was USD 1.53,
which included all inputs not paid for in cash except for
the cost of the donated azithromycin and the opportunity
cost of community members attending treatment.
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for its entire duration. Each of the vehicles was equipped with a
high frequency radio (Codan Ltd., Adelaide, Australia), a
handheld satellite phone (Thuraya, Abu Dhabi, United Arab
Emirates) and an in-car charger, to allow communication between
teams and with the field office at all times. A third vehicle and
driver were hired for one month during the campaign, but it
lacked above equipment and was not suitable for off-road driving.
The MDA campaign consisted of three distinct implementation
phases: a start-up phase amounting to a total of 57 days during
which health education and training materials were developed,
equipment was purchased and transported to the state capital
Bentiu, TATS were recruited and trained, and local authorities
were made aware of the upcoming MDA and its purpose. After
the start-up phase was complete, MDA delivery was conducted
payam-by-payam using approximately the same procedure and
timeframe in each and amounting to a total of 88 days, 27 of
which were spent on training CDDs. The procedure applied
consisted of CDD and supervisor training (2–3 days), a census in
each village (2 days), drug pick-up (1 day), MDA delivery (2 days),
and drop-off of drugs and treatment registers (1 day). The MDA
was conducted using central point or house-to-house delivery, as
agreed upon by the CDDs and the community during the census.
Once all payams had been treated, a closure phase of 24 days was
required during which equipment was transported and stored,
inventories were updated, data were entered and analysed, and a
report was prepared.
Collection of Cost Data
A detailed costing database was developed using an ingredients
approach to capture financial and economic costs as incurred by
Malaria Consortium. The costing template and methodology
described in an earlier costing study on NTD mapping in South
Sudan were used for this purpose [27]. Some costs that could not
be captured during the fieldwork were subsequently estimated
from financial expenditure records. Average exchange rates for
the period 1 May to 31 August 2010 were used for currency
conversions, as provided by OANDA (http://www.oanda.com/
currency/historical-rates). The rates were: 1 United States Dollars
(USD)=2.26 Sudanese Pound (SDG) or 1 USD=2,197 Ugandan
Shillings (UGX).
Both financial and economic costs were estimated from the
perspective of the provider [28], in this case Malaria Consortium.
The only input not captured using this approach was the time of
community members required to attend sensitization and
treatment sessions. In addition, we chose not to include the cost
of azithromycin, as ITI will donate and deliver this drug to
trachoma endemic countries for the foreseeable future. Further-
more, inclusion of the economic cost of this drug, estimated at
USD 278 per bottle of 30 tablets and USD 39 per 1,200 mg bottle
of POS (ITI, pers. com.) would have skewed the cost-estimate
towards the drug, while we were ultimately interested in estimating
a comprehensive delivery cost as incurred by the provider. The
cost of tetracycline, however, was included, as this drug has to be
procured by the provider to ensure that all eligible age groups can
be provided with trachoma treatment.
Financial costs captured were the cash expenditures made to
enable implementation of the campaign. For capital items, these
were estimated for the total number of days they were required to
organize and implement the MDA campaign using straight-line
depreciation, followed by calculation of an average financial daily
cost. Economic costs captured the value of all resources required
for the campaign, including opportunity costs of equipment that
was used but not paid for and a proportion of the costs of capital
items with a value over USD 100 and an expected useful life of
more than one year that were used in the campaign [29]. The time
of CDDs was not included as an economic cost, because they were
paid a per-diem as compensation for their time. Capital items were
discounted over their estimated useful life using the recommended
discount rate of 3% [30,31]. Daily economic costs were calculated
for all capital items and multiplied by the appropriate number of
days in use during the MDA campaign. Based on our experience
of working in the harsh environment of South Sudan, we
estimated the useful life of vehicles and high frequency radios
(fitted to vehicles) to be four years and two years for all other items.
All resources used to conduct the costing study were excluded
from the analysis. Training costs, however, which could potentially
be incurred only once if knowledge and staff were retained over
subsequent MDA rounds, were included as an integral part of the
campaign costing. This was felt to be necessary, because the study
aimed to estimate the cost of scaling up MDA to the substantial
trachoma endemic areas of South Sudan that have not been
targeted with interventions to date [32], hence incurring these
training costs, but also because high attrition of community
volunteers [11] is likely to results in the same or similar training
needs for subsequent MDA rounds in the same geographic area.
To be consistent with our previous costing study in South Sudan
[27] we applied an overhead of 25% to the financial cost estimates
for all budget lines. In our experience this estimate provides an
accurate reflection of overheads associated with implementation in
this post-conflict setting.
Outcomes
The outcome that the present analysis aimed to estimate was the
cost per person treated through an MDA campaign, regardless of
the type of antibiotic treatment or its formulation. Given that high
coverage with azithromycin and tetracycline is required for
effective control, we decided that there was no reason to
investigate potential differences in delivery costs between antibiotic
types or formulations.
Sensitivity Analyses
One-way sensitivity analyses were conducted to explore the
effects of key assumptions on the cost estimate. The effects of
varying the following parameters were explored: i) the discount
rate was reduced to 0% or increased to 10%; ii) the assumed
lifespan of vehicles was increased to 7.5 years, and iii) the exchange
rate was modified from the average of SDG 2.26 per USD
provided by OANDA to an average of SDG 2.45 per USD, as
used by the KCB bank in Juba over the implementation period.
Results
The total financial cost of the campaign amounted to USD
169,084 including a 25% overhead (Table 1). The major cost
drivers were recurrent rather than capital costs, led by personnel
(41.3%) and followed by travel/transport (29.1%) and accommo-
dation/sustenance (10.0%). The largest proportion of financial
costs was incurred during the actual MDA delivery period
(86.6%), while the start up and closure phases only required
moderate investment (Table 2). The total economic cost was USD
189,889, including the same overhead as that included in the
financial cost (Table 1). Economic costs were slightly higher than
financial costs, because this estimate captured non-financial
contributions to the implementation of the campaign. The
difference between these two estimates was greatest for the
categories of accommodation/sustenance and MDA/IEC con-
sumables and other charges (Table 1), largely because the team
The Cost of Antibiotic Delivery in Southern Sudan
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organizations during part of the campaign and because the state/
county administrations provided the training facilities. In other
settings, even within Unity state, these contributions would have to
be paid for, which is why they were included as part of the
economic costs.
The MDA campaign delivered antibiotic treatments to a total of
123,760 individuals in Mayom county, which translated into 94%
coverage of the estimated population. For the first time ever this
area benefitted from at least one of the component of the SAFE
strategy for trachoma control. The average economic cost per
person treated was USD 1.53, excluding the cost of azithromycin.
If the economic cost of the donated antibiotic had been included,
the estimated economic cost per person treated would have been
USD 34.2 (data not shown).
Varying the underlying assumptions had limited effect on the
estimated economic cost per person treated (Table 3). Most
pronounced was the use of the exchange rate applied by the main
bank in Juba, as opposed to the figure provided by OANDA,
reducing the cost per person treated to USD 1.48.
Discussion
The aim of the present analysis was to estimate the cost of
delivering one, or possibly more, drug(s) through MDA campaigns
in South Sudan, thus informing budgeting for control of trachoma
Table 1. Financial and economic costs, and associated cost profiles, for antibiotic MDA in Mayom County.
Total financial cost (USD) % of financial cost* Total economic cost (USD) % of economic cost*
Capital costs
Vehicles 5,369 4.0% 5,718 3.7%
Communication & IT equipment 558 0.4% 601 0.4%
Accommodation equipment 446 0.3% 467 0.3%
MDA & IEC equipment 2,348 1.7% 2,469 1.6%
Subtotal 8,721 6.4% 9,255 5.9%
Recurrent costs
Travel & transport 39,306 29.1% 39,465 25.3%
Vehicle fuel & maintenance 3,384 2.5% 3,384 2.2%
Accommodation & sustenance 13,513 10.0% 22,479 14.4%
MDA & IEC consumables & other charges 8,063 6.0% 17,449 11.2%
Drugs (tetracycline/azithromycin) 5,116 3.8% 5,116 3.3%
Communication 1,246 0.9% 1,246 0.8%
Personnel 55,919 41.3% 57,679 37.0%
Subtotal 126,546 93.6% 146,817 94.1%
Subtotal 135,267 156,072
Overhead (25%) 33,871 33,817**
Total 169,084 189,889
Number of persons treated 123,760 123,760
Cost per person treated 1.37 1.53
*Proportions were calculated on the subtotal, i.e. excluding the overhead.
**Overhead as calculated for financial costs.
doi:10.1371/journal.pntd.0001362.t001
Table 2. Financial and economic costs, and associated cost profiles, for the three phases of antibiotic MDA.
Total financial cost (USD) % of financial cost* Total economic cost (USD) % of economic cost*
Campaign phases
Start-up phase 13,470 10.0% 18,907 12.1%
MDA delivery 117,086 86.6% 129,784 83.2%
Closure phase 4,711 3.5% 7,381 4.7%
Subtotal 135,267 156,072
Overhead (25%) 33,817 33,817**
Total 169,084 189,889
*Proportions were calculated on the subtotal, i.e. excluding the overhead.
**Overhead as calculated for financial costs.
doi:10.1371/journal.pntd.0001362.t002
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that a first round of MDA in the remote area of Mayom county
incurred an economic cost of USD 1.53 per person treated. This
estimate was considerably higher than that of USD 0.5, frequently
quoted as the approximate annual per capita cost for simultaneous
delivery of multiple drugs to control some key NTDs [6–8]. This
substantial difference between the two cost estimates can largely be
explained by the fact that the latter figure is not based on in-depth
costing work for a specific setting.
In the present case, the setting was one of the hardest to reach,
and hence most costly implementation areas in Sub-Saharan
Africa. Moreover, logistical and financial delays meant that
implementation had to be conducted during the rainy season,
slowing down fieldwork. In addition, this was the first MDA round
for trachoma control in Mayom county, necessitating a start-up
period to develop the training and health education materials,
develop a baseline list of villages, which did not exist previously,
and develop the most practical MDA implementation methodol-
ogy. The cost estimate may therefore be considered a ‘worst-case
scenario’, rather than a figure that is generally applicable for large-
scale PCT (co-)administration in other parts of Sub-Saharan
Africa, although this remains to be confirmed. Our estimate would
certainly be applicable to the delivery of first rounds of antibiotics
or other PCT for NTD control in most areas of South Sudan, as
the remoteness and operational constraints of Mayom are the rule
rather than an exception in this country.
Unfortunately it is hard to judge how our estimate compares to
other settings, as we were unable to identify any other estimates of
the delivery cost for trachoma MDA that were directly
comparable to the approach used here. The seemingly most
comparable result was obtained as part of a comparison of
different treatment strategies in Mali [21]. Costs were, however,
not directly estimated during the study but extrapolated from data
provided by the Malian National Programme for Prevention of
Blindness for antibiotic distribution at district level. Assuming the
drug was free of charge and including an estimate of the societal
cost associated with attending the distribution, the study arrived at
an estimated cost per person treated of USD 0.25 for mass
treatment of all residence [21]. It is unclear whether this estimate
was derived using the same ingredients as in the present study.
One ingredient that was clearly not included in the analysis from
South Sudan was the opportunity cost of the people attending
treatment. Two methods – central point or house-to-house
distribution – were used in Mayom depending on the communi-
ties’ decision, but no data were collected on which approach was
used where. It was therefore not feasible to include the correct
economic cost associated with community members attending
distribution, or to establish whether there may have been a
difference in cost between the two distribution methods.
Drug delivery costs in South Sudan would likely be slightly
lower in areas nearer the capital Juba, as this would reduce the
high transport costs. In the present case, supplies and equipment
had to be brought from Juba to Unity, a journey taking at least
three days by truck. Implementation in areas near Juba may also
be conducted over a shorter timeframe, because accessibility of
communities is generally better and a higher proportion of the
community is literate. Furthermore, the population density near
the capital is higher, meaning that it may be feasible to treat more
people with similar inputs, for example by utilizing more central
point than house-to-house distribution. This could increase the
denominator and hence decrease the cost per person treated.
Costs may also decrease when the materials and experience
developed during the initial campaign are applied in subsequent
rounds. Further cost analysis by implementing partners is clearly
required to answer these questions and assist in future budgeting.
Given our experience of operating in South Sudan, we
nevertheless feel that implementation in areas other than Mayom
county and the delivery of subsequent, rather than initial, MDA
rounds are unlikely to lead to significant cost savings. Most
trachoma endemic areas of South Sudan are remote, with
households dispersedly located, and hence comparable to Mayom.
Staff turnover including that of CDDs is high [11], resulting in loss
of institutional memory and requiring a large amount of costly re-
training from year to year. In the present MDA round there was
also no obvious opportunity to increase the scale of the
intervention with existing resources, as the core MDA team had
no spare capacity to allow coverage of additional areas. Scaling up
geographical coverage while maintaining quality, safety and at
least 90% population coverage would thus be associated with
hiring more personnel and using more transport resources, both of
which drove the overall implementation cost in the Mayom
campaign and would lead to a similar delivery cost per person
treated if the same approach was scaled up. For subsequent MDA
campaigns in Mayom, as well as for the scale up of trachoma
control to all other counties of Unity state, it therefore seems
prudent to budget an average cost of USD 1.5 per person treated,
unless obvious cost savings are identified during repeated rounds.
Accordingly, the estimated cost of treating the population in all
nine trachoma endemic counties of Unity State would exceed
USD 1 million annually and require a yearly donation of
azithromycin valued at USD 16 million.
Further costing work on drug delivery through community-
based distribution mechanisms in South Sudan and elsewhere
would be useful, particularly with regards to estimating the actual
cost and cost-effectiveness of co-administering PCT in areas
endemic for more than one NTD [33]. In the present case, the
intervention area is also endemic for schistosomiasis (Malaria
Consortium, unpublished) and is being targeted by a programme
for integrated community-case management (iCCM) to treat
malaria, pneumonia and diarrhoea [34,35]. While drug safety
recommendations would currently not allow the co-administration
of antibiotics with praziquantel for schistosomiasis control [25],
there may be ways in which iCCM and its support/supervision
system could be harnessed to contribute to trachoma and/or
schistosomiasis control. There was some collaboration between the
trachoma and iCCM intervention during this first MDA round,
but both interventions had only just started and were largely
concerned with achieving their own objectives rather than
exploring opportunities for integration. Now that iCCM has been
Table 3. Sensitivity of economic cost estimate to underlying
assumptions.
Assumptions tested USD/person treated
% deviation from
base case
Base case 1.53 -
Discount rate:
0% 1.53 0%
10% 1.55 +1.3%
Vehicle lifespan:
7.5 years 1.51 21.3%
Exchange rate (SDG/USD):
2.45 1.48 23.3%
doi:10.1371/journal.pntd.0001362.t003
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resources are required to deliver MDAs for trachoma and
schistosomiasis control as part of this structure rather than through
a vertical campaign, and whether this is likely to be as effective but
cheaper. Similarly, further experience and cost data is urgently
required to determine how South Sudan could establish an
innovative platform for community-based delivery of a broad
range of public health interventions; one of the opportunities
offered by this post-conflict setting that has not been taken up [11].
Conclusion
In a remote setting and for the initial round, the delivery of
antibiotics for trachoma control through an MDA campaign was
three times as expensive as the figure commonly used in
international advocacy for simultaneous delivery of a package of
drugs to prevent or treat multiple NTD. Costs for delivering one
or more drug(s) through MDA campaigns in South Sudan are
unlikely to decrease substantially during subsequent rounds, as the
major cost drivers were recurrent costs and unlikely to decline
dramatically. Until further cost data are generated, MDA
campaigns in South Sudan should thus be budgeted at a delivery
cost of about USD 1.5 per person targeted.
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